目的 研究天津市人民医院口服降糖药的使用情况，为临床合理应用提供参考。方法 对2014-2016年天津市人民医院口服降糖药的用量、销售金额、用药频度（DDDs）、日均药费（DDC）等进行统计和分析。结果 2014-2016年，口服降糖药的品种、总销售金额及总DDDs均保持稳定；α-糖苷酶抑制剂、磺酰脲类促胰岛素分泌剂、双胍类DDDs占主导地位，构成比占80%以上；促胰岛素分泌剂和DPP-4抑制剂的DDDs呈逐年增长趋势。阿卡波糖、二甲双胍、伏格列波糖的DDDs排名稳居前3位；格列喹酮、那格列奈、沙格列汀、阿格列汀的DDDs增长速度较快。2016年因价格政策影响，口服降糖药的DDC略有下降，阿卡波糖的DDC最高，格列齐特最低。阿卡波糖、格列美脲、吡格列酮、那格列奈、格列吡嗪、格列齐特、沙格列汀、阿格列汀的B/A值接近或等于1。结论 天津市人民医院口服降糖药的使用基本合理，α-糖苷酶抑制剂、磺酰脲类促胰岛素分泌剂、双胍类为临床首选药品。

Objective To evaluate the usage of oral antidiabetic drugs in Tianjin Union Medicine Centre, in order to provide a reference for clinical rational drug use. Methods Amounts, consumption sum, defined daily doses (DDDs), and defined daily cost (DDC), etc. in Tianjin Union Medicine Centre fom 2014 to 2016 were analyzed statistically. Results Consumption sum and DDDs were stable in general for three years. Glycosidase inhibitors, sulfonylureas, and biguanides accounted for 80% of DDDs. DDDs of insulin secretagogues and DPP-4 inhibitors were increased year by year. Acarbose, metformin, and voglibose kept top three in respect of DDDs. Gliquidone, nateglinide, saxagliptin, and alogliptin showed a rapid upward trend as single-drug. DDC of oral antidiabetic drugs dropped influenced by price policy in 2016. DDC of acarbose was the highest, and gliclazide was the lowest. B/A of acarbose, glimepiride, pioglitazone, nateglinide, glipizide, saxagliptin, and alogliptin were next to 1. Conclusion The application of oral antidiabetic drugs in Tianjin Union Medicine Centre is basically rational. Glycosidase inhibitors, sulfonylureas, and biguanides are preferred in clinic.